Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 16 for:    ZOLPIDEM AND Chronic Insomnia

Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02671760
Recruitment Status : Completed
First Posted : February 2, 2016
Results First Posted : March 6, 2018
Last Update Posted : March 6, 2018
Sponsor:
Collaborator:
Clinilabs, Inc.
Information provided by (Responsible Party):
Sequential Medicine Ltd

Brief Summary:
The purpose of this study is to evaluate the effect of a combination drug product containing diphenhydramine, zolpidem and lorazepam on total sleep time. Participants will be adults who sometimes have difficulty falling asleep or staying asleep, but who do not have chronic insomnia. The study involves 3 one-night stays in a sleep center in New York City.

Condition or disease Intervention/treatment Phase
Short-term Insomnia Drug: SM-1 Drug: Comparator Drug: Placebo Phase 2

Detailed Description:

The purpose of this study is to evaluate the effect of a combination drug product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam on total sleep time, and to determine the contribution of diphenhydramine to the combination, using a 5-hour Phase Advance model of sleep challenge. This is a 3-arm cross-over study; each participant will receive 3 single-dose treatments on consecutive visits. The 3 arms are: investigational combination product, placebo, and a 2-drug comparator containing the zolpidem and lorazepam components but not diphenhydramine. Participants will be adults who sometimes have difficulty falling asleep or staying asleep, but who are generally healthy and do not have chronic insomnia or sleep apnea.

A total of 39 subjects are being recruited. Subjects who qualify for participation will be asked to keep a sleep diary to document their sleep times leading up to and during the study, and will be asked to spend 7-8 hours in bed at a regular bedtime during the study. Qualifying participants also will not anticipate significant disruptions in their sleep schedules, for example by traveling across timezones or changing shifts at work, during the study. The study requires 3 one-night stays in a sleep center in New York City, for administration of the study treatments and EEG measurements. Qualifying subjects will anticipate being able to return to the sleep center, located in Manhattan, for a total of 4 visits, including initial screening and 3 treatment times.

During each sleep center visit, subjects will be given their study treatment and be put to bed 5 hours before their usual bedtime, and sleep time will be monitored for 8 hours. Each subject will receive all 3 treatments, although the sequence of the 3 treatments will be randomized. Both subjects and study personnel monitoring the subjects will be blinded to the identity of the treatment administered at each visit.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Single-Dose Study to Assess the Pharmacodynamic Effects of SM-1 Versus Comparator and Placebo in a 5 Hour Phase Advance Model of Insomnia in Adults Who Suffer From Short-Term Insomnia
Study Start Date : February 2016
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Arm Intervention/treatment
Experimental: Treatment
SM-1
Drug: SM-1
3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam

Active Comparator: Comparator
2-drug combination
Drug: Comparator
2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam

Placebo Comparator: Placebo
Placebo
Drug: Placebo
Placebo




Primary Outcome Measures :
  1. Total Sleep Time [ Time Frame: 8 hours ]

Secondary Outcome Measures :
  1. Latency to Persistent Sleep [ Time Frame: 8 hours ]
    Time it takes to fall asleep

  2. Awakenings [ Time Frame: 8 hours ]
  3. Latency to REM Sleep Onset [ Time Frame: 8 hours ]
    Time required to achieve REM sleep

  4. Adverse Events [ Time Frame: 8 hours ]
    Safety and tolerability assessed in terms of the incidence of AEs

  5. Safety and Tolerability in Terms of Residual Sleepiness [ Time Frame: 8 hours ]
    Karolinska Sleepiness Scale. This is a 9-point scale with values ranging from 1 (extremely alert) to 9 (extremely sleepy). Lower scores indicate less residual sleepiness.

  6. Safety and Tolerability in Terms of Residual Sleepiness [ Time Frame: 8 hours ]
    Digit Symbol Substitution Test. The test score is number of correct answers in 90 seconds. Higher scores indicate favorable response (i.e., less residual sleepiness). The duration of the challenge is the 90 second time limit; there is no theoretical maximum score to attain.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body mass index (BMI) between 19 and 32 kg/m2, inclusive;
  • Report occasional difficulty falling asleep or staying asleep;
  • Report a regular, habitual bedtime between 21:00 and 24:00, routinely spend at least 7.5 and no more than 9.0 hours in bed each night and observe a bedtime that does not vary by more than 2 hours over the course of the week. Subjects will be required to complete at least 5 days of sleep information in a diary provided at the screening visit and returned to study personnel no later than 24 hours prior to check-in for the first overnight visit.
  • Be in good general health as determined by a thorough medical history and physical examination including vital signs and clinical laboratory tests;
  • Females of childbearing potential must be using an acceptable method of contraception, have a negative serum pregnancy test at screening and have a negative urine pregnancy test before randomization and prior to each Treatment Period. Acceptable methods of contraception include oral, intrauterine and injectable contraceptives or double barrier methods. After screening, subjects using oral contraceptives must agree to add a double barrier method until 30 days following the last dose of study medication. Female subjects relying on oral contraceptives must have been using them for at least one month prior to screening;
  • Female subjects who have been surgically sterilized are eligible if they have a negative serum pregnancy test at screening and negative urine pregnancy test at check-in for Visits 2 and 3, or are post-menopausal as defined by the cessation of menses for a period of at least 2 years prior to screening or have had a complete hysterectomy;
  • Male subjects must use an acceptable method of contraception during the course of the study and for the 30 days following the last dose of study medication. Acceptable methods of contraception include:

    1. Abstinence
    2. A condom and one of the following:

    i. Vasectomy for more than 6 months. ii. Female partner who meets one of the following conditions:

    1. Uses a spermicidal gel or foam; or
    2. Has had a tubal ligation, hysterectomy or bilateral oophorectomy; or
    3. Is post-menopausal (menopause is defined as over the age of 60 years, or between 45 and 60 years being amenorrheic for at least 2 years with plasma follicle stimulating hormone (FSH) level > 30 UI/L); or
  • Be able to read, understand, and provide written/dated informed consent before enrolling in the study and must be willing to comply with all study procedures;
  • Be willing and able to be confined to the clinical research site for one night in each of 3 treatment periods as required by the protocol.
  • Refrain from alcohol on PSG days;
  • On the days of check-in for each of the study's two treatment periods, refrain from the use of alcohol and from napping, defined as any sleep episode occurring outside of the subject's main sleep episode of the day;
  • Report a recent history of napping of no more than once per week.
  • An Epworth Sleepiness Scale score ≤8 at screening.

Exclusion Criteria:

  • Clinically significant, acute illness within 14 days prior to screening (Visit 1).
  • Clinically significant, unstable medical illness;
  • Evidence or history of clinically significant allergic (except for untreated, asymptomatic, seasonal allergies at time of dosing), hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic or neurological disease;
  • History of cancer or diabetes;
  • A supine blood pressure > 140/90 millimeters mercury (mm/Hg) at screening;
  • Heart rate > 100 beats per minute (BPM) at screening;
  • Clinically significant psychiatric illness, including chronic psychiatric illness or the history or presence of any Axis I condition;
  • History or presence of chronic pain;
  • Lifetime history of seizure disorder or serious head injury;
  • Clinically significant sleep disorder, including insomnia, sleep apnea, narcolepsy, parasomnia, restless leg syndrome or circadian rhythm disorder;
  • Any condition that may affect drug absorption;
  • Travel across more than three time zones, an expected change in sleep schedule or involvement in night shift work within one month prior to screening or during the study period;
  • Any clinically significant abnormal finding on physical examination, vital signs or clinical laboratory tests, as determined by the Investigator;
  • History of allergies, or known sensitivity, hypersensitivity, or adverse reaction to any drug similar to diphenhydramine, zolpidem or lorazepam;
  • Pregnant or lactating females;
  • Positive serum pregnancy test at Visit 1 or positive urine pregnancy test at check-in for Visit 2 or 3;
  • Positive urine drug screen at the Visit 1;
  • Recent history (≤ one year) of alcohol or drug abuse, or current evidence of substance dependence or abuse as defined by DSM-V criteria;
  • Regular consumption of "large amounts" of xanthine-containing substances (i.e., more than 500 mg of caffeine per day or equivalent amounts of xanthine-containing substances);
  • Self-report of a usual consumption of more than 14 units of alcohol per week. One unit of alcohol is equivalent to 12 ounces of beer, 4 ounces of wine or 1 ounce of liquor;
  • Use of more than 10 products containing nicotine per day or routinely smokes during sleep period
  • Discontinuation of smoking or participation in a smoking cessation program within 90 days of screening;
  • Any use with the six months prior to screening of restricted concomitant medications including prescription hypnotics, antidepressants, anxiolytics, anticonvulsants or narcotics;
  • Use of any prescription drug, OTC medication, grapefruit juice, herbal preparation or food supplement, excluding vitamins, acetaminophen or hormonal contraceptives within two weeks of randomization;
  • Use of any investigational drug within 30 days prior to screening or any prior exposure to the study drugs diphenhydramine, zolpidem or lorazepam or other drugs of the same pharmaceutical classes;
  • Positive alcohol breathalyzer test at the time of screening or prior to dosing at Visit 2, 3 or 4.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02671760


Sponsors and Collaborators
Sequential Medicine Ltd
Clinilabs, Inc.
Investigators
Layout table for investigator information
Study Director: Thomas Dahl, PhD Sequential Medicine Ltd
Principal Investigator: Maha Ahamad, MD Clinilabs, Inc.

Layout table for additonal information
Responsible Party: Sequential Medicine Ltd
ClinicalTrials.gov Identifier: NCT02671760     History of Changes
Other Study ID Numbers: SM-A-02
First Posted: February 2, 2016    Key Record Dates
Results First Posted: March 6, 2018
Last Update Posted: March 6, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Sequential Medicine Ltd:
Short-term insomnia
difficulty sleeping
sedative
hypnotic
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders